Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors
Xinyu Liu(Hebei Medical University), Jingnan Li(Peking Union Medical College Hospital), Hao Tang(Second Military Medical University), Bo Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingyang Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Bei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinmiao Jia(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanlin Zeng(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Peking Union Medical College Hospital), Xiaoxing Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 40
Related Papers
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Chinese Consensus Report on Family-Based<i>Helicobacter pylori</i>Infection Control and Management (2021 Edition)
|Gut|2021|183
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
|Annals of Oncology|2013|126
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
|The Lancet Regional Health - Western Pacific|2023|112